Michael J.m. Hitchcock has bought BMEA on 2 days since Sep 2024

Dr. Michael J.M. “Mick” Hitchcock is the Interim Chief Executive Officer and a director of Biomea Fusion, Inc. (NASDAQ: BMEA), a clinical‑stage company focused on developing oral covalent small‑molecule therapies for diabetes and obesity.( A member of Biomea Fusion’s board since March 2021, he was appointed Interim CEO in March 2025 following the leadership transition in which co‑founder Thomas Butler stepped down as CEO and chairman.( As Interim CEO, Hitchcock oversees the company’s strategic pivot to metabolic disease, including its decision in early 2025 to discontinue oncology programs and concentrate resources on diabetes and obesity medicines.( He has also been aligned with shareholders through equity compensation, including a multi‑year stock‑option grant reported in 2026.(

Hitchcock’s career in pharmaceutical research and development began at Bristol‑Myers Squibb, where he held infectious‑disease research and project‑planning roles from 1980 to 1993.( He then joined Gilead Sciences in 1993, spending 27 years in positions of increasing responsibility, including vice president roles in project and portfolio management, alliance management, strategic planning, medical affairs, and specific research areas.( Outside of industry, he is a Past Chair of the University of Nevada, Reno (UNR) Foundation and has served since 2016 as an adjunct professor of microbiology at the UNR School of Medicine.( Hitchcock holds a Ph.D. (field not specified in public filings) and is recognized for combining deep R&D experience with long‑term strategic leadership in the biopharmaceutical sector.(

Written by Perplexity from public sources.